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ABSTRACT Phosphoethanolamine (PEA) on Neisseria gonorrhoeae lipid A influences gonococcal inflammatory signaling and
susceptibility to innate host defenses in in vitro models. Here, we evaluated the role of PEA-decorated gonococcal lipid A in com-
petitive infections in female mice and in male volunteers. We inoculated mice and men with mixtures of wild-type N. gonor-
rhoeae and an isogenic mutant that lacks the PEA transferase, LptA. LptA production conferred a marked survival advantage for
wild-type gonococci in the murine female genital tract and in the human male urethra. Our studies translate results from test
tube to animal model and into the human host and demonstrate the utility of the mouse model for studies of virulence factors of
the human-specific pathogen N. gonorrhoeae that interact with non-host-restricted elements of innate immunity. These results
validate the use of gonococcal LptA as a potential target for development of novel immunoprophylactic strategies or antimicro-
bial treatments.
IMPORTANCE Gonorrhea is one of the most common bacterial sexually transmitted infections, and increasing antibiotic resis-
tance threatens the use of currently available antimicrobial therapies. In this work, encompassing in vitro studies and in vivo
studies of animal and human models of experimental genital tract infection, we document the importance of lipid A’s structure,
mediated by a single bacterial enzyme, LptA, in enhancing the fitness of Neisseria gonorrhoeae. The results of these studies sug-
gest that novel agents targeting LptA may offer urgently needed prevention or treatment strategies for gonorrhea.
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Gonorrhea remains a global health problem. The worldwide inci-dence of Neisseria gonorrhoeae infection equaled or surpassed
that of Chlamydia trachomatis as the most common bacterial sexually
transmitted infection for the first time in 2008 (1). Increasing bacte-
rial resistance to antibiotics used to treat gonorrhea, coupled with a
dearth of new antimicrobial therapies in development, raises the
specter of incurable N. gonorrhoeae infections (2). The potential of
adverse reproductive health consequences of untreatable gonococcal
infections as well as increased HIV transmission in areas where both
infections are prevalent is alarming (3). Identification of new thera-
peutic and vaccine targets for gonorrhea may be more important now
than ever before.
The most abundant lipid constituent of the N. gonorrhoeae
outer membrane is lipooligosaccharide (LOS), a glycolipid com-
prised of an antigenically variable oligosaccharide core (4) at-
tached to lipid A, which is frequently decorated by phosphoetha-
nolamine (PEA) at the 4= position (5, 6). The presence or absence
of PEA-decorated lipid A (PEA-lipid A) profoundly influences
inflammatory signaling (7, 8) and bacterial susceptibility to innate
host defenses, including the bactericidal activities of normal hu-
man serum, complement, and cationic antimicrobial peptides
(CAMPs) (5, 9). To assess the importance of this structure during
human infection, we constructed PEA transferase (lptA) deletion
mutants of N. gonorrhoeae strain FA1090, which cannot add PEA
to lipid A, and tested FA1090 lptA in competitive infections with
isogenic lptA gonococci in the female murine lower genital tract
and the human male urethra.
Strains. N. gonorrhoeae FA1090 is a porin serotype PIB-3,
streptomycin (Sm)-resistant strain that has been used extensively
in experimental human infection studies (10). Bacteria were cul-
tured on gonococcal agar (GC agar) supplemented with Kellogg’s
supplement I and ferric nitrate or in GC broth as described previ-
ously (11) with or without antibiotics as appropriate. Cultures
were incubated at 35 to 37°C with 5 to 7% CO2.
FA1090 lptA was constructed without altering the antibiotic
susceptibility of the wild-type strain, as previously described (12).
Briefly, a two-gene cassette containing both a selectable marker
(chloramphenicol [Cm] acetyltransferase [CAT] conferring Cm
resistance) and a counterselectable marker (rpsL, conferring Sm
sensitivity on the naturally resistant strain FA1090) was cloned
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into the lptA gene and used to replace the wild-type gene in the
FA1090 chromosome by allelic exchange; transformants were se-
lected on GC agar with 1 g Cm/ml. The resulting intermediate
strain was Cm resistant and Sm sensitive. A second transforma-
tion replaced the CAT rpsL cassette with an unmarked deletion
encompassing approximately 80% of the lptA coding sequence;
transformants were selected on GC agar with 100 g Sm/ml. The
resulting strain, FA1090 lptA, was Cm sensitive and Sm resistant,
as is wild-type strain FA1090. PCR amplification of the lptA locus
and analysis of the FA1090 lptA genome sequence confirmed
deletion of the gene in the mutant. The wild-type lptA gene from
strain FA19 (identical to that of FA1090) was introduced into the
FA1090 deletion mutant using the pGCC4 lptA vector as previ-
ously described (5). The wild-type lptA gene is under the control
of a lac promoter and is positioned between lctP and aspC in
C=FA1090 lptA.
Electrophoretic characterization of gonococcal LOS and lipid A
biochemical analyses. Whole-cell proteinase K-digested lysates of
gonococci were resolved by Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, and LOS bands were identified by
silver staining and Western blotting with monoclonal antibody 3F11
as previously described (9). Lipooligosaccharides were purified from
N. gonorrhoeae strains grown in GC broth, and lipid A was isolated by
mild acid hydrolysis as previously described (9). Lipid A was purified
by extraction with chloroform and methanol; purified material was
used for compositional analysis and determination of mass by
matrix-assisted laser desorption ionization–time of flight mass spec-
trometry (MALDI-TOF MS) using a model 4700 proteomics ana-
lyzer instrument (Applied Biosystems). Oligosaccharides were puri-
fied by size exclusion column chromatography; linkage analysis was
performed by gas chromatography-mass spectrometry (GC-MS) us-
ing an Alltech AT-1 fused-silica capillary column on a Hewlett-
Packard HP5890 gas chromatograph equipped with mass selective
detector 5970 MSD.
PMB MIC determination. MICs of polymyxin B (PMB) were
determined by spotting approximately 105 CFU of N. gonorrhoeae
suspensions onto GC agar containing 2-fold differences in PMB,
from 0.19 to 200 g PMB/ml; the MIC was defined as the highest
concentration of PMB at which bacterial growth was observed
after a 24-h incubation.
Experimental murine infection. All animal experiments were
conducted at the Uniformed Services University of the Health
Sciences according to the guidelines of the Association for the
Assessment and Accreditation of Laboratory Animal Care under a
protocol that was approved by the University’s Institutional Ani-
mal Care and Use Committee. Female BALB/c mice (6 to 8 weeks
old; National Cancer Institute) were treated with water-soluble
17-estradiol and antibiotics to increase susceptibility to N. gon-
orrhoeae as described previously (13). Groups of mice were inoc-
ulated intravaginally with wild-type FA1090 combined with sim-
ilar numbers of FA1090 lptA or C=FA1090 lptA CFU (total
dose, 106 CFU N. gonorrhoeae; 7 mice/group). Vaginal swabs were
collected every other day for 6 days starting on day 2 postinocula-
tion and suspended in 100 l GC broth. Vaginal swab suspensions
and inocula were cultured quantitatively on GC agar with 100 g
Sm/ml (total number of CFU) and GC agar with Sm plus 10 g
PMB/ml (FA1090 or C=FA1090 lptA CFU).
Experimental human infection. Procedures for participant
recruitment, informed consent, intraurethral inoculation, and
antibiotic treatment were as previously described (11). Experi-
mental human infections were conducted in the Clinical and
Translational Research Center of the North Carolina Transla-
tional and Clinical Sciences Institute at the University of North
Carolina at Chapel Hill according to the guidelines of the U.S.
Department of Health and Human Services and the University’s
Institutional Review Board under a protocol that was approved as
a U.S. investigational new device (IND). All study participants
provided written informed consent. In two separate trials, volun-
teers received approximately equal numbers of N. gonorrhoeae
FA1090 and FA1090 lptA CFU (total dose, 105 to 106 CFU
N. gonorrhoeae; 3 men/trial). Gonococci in the inoculum suspen-
sions were predominantly opacity-associated adhesin (Opa) neg-
ative and piliated and expressed the same PilE sequence as previ-
ously characterized FA1090 variants used in experimental human
infection studies (14). First-void urine specimens were obtained
daily after inoculation. Urine sediment was cultured quantita-
tively on GC agar with 3 g vancomycin, 12.5 units nystatin, and
5 g trimethoprim lactate/ml, which permits the growth of
FA1090 and FA1090 lptA. Up to 96 colonies per subject per
culture were replica plated on GC agar with and without 7.5 g
colistin/ml to distinguish the 2 strains; only wild-type FA1090
grows in the presence of the polycationic antibiotic colistin.
Competitive index calculations and statistics. For experi-
mental murine and human infections, results were expressed as
the competitive index (CI) for infected individuals using the equa-
tion CI  [mutant CFU (output)/wild-type CFU (output)]/[mu-
tant CFU (input)/wild-type CFU (input)]. For murine infections,
in which total CFU and wild-type CFU were enumerated directly
from vaginal specimen cultures, the limit of detection of 1 CFU
was assigned for a strain that was not recovered from an infected
mouse. For human infections, in which total CFU were enumer-
ated directly from urine sediment cultures and up to 96 CFU per
specimen was subcultured to identify wild-type or mutant colo-
nies, the limit of detection (1/96 CFU) was assigned for the output
proportion of a strain that was not detected from an infected man.
A CI of 1 indicates that the mutant is less fit than the wild-type
strain. For experimental human infections, we also compared the
proportion of wild-type FA1090 among recovered N. gonorrhoeae
isolates on the final day of participation for each infected subject
to the proportion in the inoculum using a single-sample t test,
with the proportion for the null hypothesis equal to 0.54 (the
mean proportion of strain FA1090 in the inoculum). With a
clearly directional hypothesis that the lptA strain would predom-
inate, we used SigmaStat for Windows, v3.5 (Systat Software,
Inc.), to calculate one-tailed statistics, with the type I error rate
controlled at 0.05.
Lack of LptA-mediated PEA attachment to lipid A renders
N. gonorrhoeae susceptible to a model CAMP in vitro. PEA ad-
dition at the 4= position of FA1090 lipid A was abrogated in
FA1090 lptA and restored in the complemented strain C=FA1090
lptA (see Fig. S1A to D in the supplemental material). All strains
produced 4.2- and 4.5-kDa LOS species; the former reacted with
monoclonal antibody 3F11 (data not shown), confirming the
presence of the lacto-N-neotetraose epitope associated with nat-
urally acquired gonococcal urethritis (15). As expected, deletion
of lptA rendered FA1090 hypersusceptible to the model CAMP
PMB (MICs, 100 g PMB/ml for FA1090 versus 0.78 g PMB/ml
for FA1090 lptA), which was reversed by 32-fold in the comple-
mented strain (data not shown). Importantly, in vitro growth rates
of FA1090 lptA and wild-type FA1090 were indistinguishable
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(data not shown), and the lptA mutant did not show a fitness
difference from wild-type FA1090 when cocultured in vitro
through stationary phase in the absence of selective pressure (data
not shown). From mixtures containing similar numbers of lptA
mutant and wild-type FA1090 cells exposed to 5 g PMB/ml for
45 min in vitro, only wild-type N. gonorrhoeae with PEA-lipid A
survived (data not shown), confirming the importance of this
structure in CAMP resistance.
LptA-mediated PEA attachment to lipid A confers a survival
advantage to N. gonorrhoeae during competitive infection in
mice. Experimental infection of female BALB/c mice has been
used to study innate host defenses against N. gonorrhoeae and the
mechanisms by which gonococci evade these defenses (16–18).
Groups of female BALB/c mice were inoculated intravaginally
with mixtures containing similar numbers of wild-type FA1090
and either FA1090 lptA or C=FA1090 lptA CFU (total dose, 5 
106 to 7  106 CFU). The relative number of colonies of each
strain recovered from vaginal swabs from infected mice was de-
termined for up to 6 days after inoculation; output ratios of the
two strains were normalized to the ratio of strains in the inocu-
lum. We observed a 10- to 10,000-fold decrease in recovery of the
lptA mutant relative to the wild-type parent strain FA1090 on days
2 to 6 of infection (Fig. 1A). No mutant bacteria were recovered
from several mice on multiple days postinoculation, whereas
wild-type gonococci were recovered from these mice at levels of
103 to 106 CFU/ml vaginal swab suspension (Fig. 1A, open
circles). Complementation of lptA restored recovery of the mutant
by day 6 postinoculation (Fig. 1B). Packiam et al. recently showed
similar results with gonococcal strain FA19 during competitive
infection in mice (19).
LptA-mediated PEA attachment to lipid A confers a survival
advantage to N. gonorrhoeae in the male urethra. To determine
potential influences of host restriction differences in mice and
humans (as well as differences in female and male genital tracts)
on the contribution of PEA-lipid A to in vivo gonococcal survival,
we performed competitive infections with wild-type N. gonor-
rhoeae FA1090 and the lptA mutant in the human challenge model
of gonococcal urethritis (10). Six subjects were inoculated intra-
urethrally with approximately equal mixtures of FA1090 and
FA1090 lptA (total dose, 105 to 106 CFU). Five subjects (83%)
developed gonococcal urethritis 2 to 4 days after inoculation; one
remained uninfected for 5 days after inoculation (Table 1). The
relative number of each strain recovered was determined by sub-
culturing up to 96 colonies from each positive urine sediment
culture on selective media; output ratios of the two strains were
normalized to the ratio of strains in the inoculum. Among colo-
nies tested, only wild-type FA1090 was recovered (Table 1). We
observed the maximum possible 100-fold decrease in the recovery
of the lptA mutant relative to that of wild-type FA1090 on days 2 to
4 of infection (Fig. 1C).
In our competitive infection studies, PEA-lipid A clearly pro-
vided a substantial fitness benefit to gonococci during infection,
both in the human male urethra and in the murine female genital
tract, compared to N. gonorrhoeae lacking PEA attached to lipid A.
The mouse model likely underestimates the importance of PEA-
lipid A during infection due to differences in human and murine
complement-binding proteins. However, some factors are appar-
ently not host restricted (e.g., CAMP-mediated killing of the lptA
mutant), confirming that the murine model can provide impor-
tant information regarding the pathogenesis of gonococcal infec-
tion that is translatable to humans. In the mouse model, reduced
infectivity resulting from lptA deletion in N. gonorrhoeae strain
FA19 occurs only during competitive infections; noncompetitive
infections with wild-type FA19, the FA19 lptA mutant, or the
complemented FA19 lptA mutant produce similar kinetics of vag-
inal colonization and bacterial recovery (19). However, only wild-
type N. gonorrhoeae FA19 and the complemented FA19 lptA mu-
tant induce proinflammatory host responses to gonococcal
infection in female mice. John and colleagues previously demon-
strated reduced inflammatory stimulation of human THP-1 cells
by an lptA null mutant of the related pathogen N. meningitidis and
by commensal Neisseria species that lack lptA (20). Thus, PEA
decoration of gonococcal lipid A not only increases inflammatory
responses in vitro and during murine infection but also protects
N. gonorrhoeae from the consequences of inflammation, including
increased CAMP production. Experimental human infection
FIG 1 PEA decoration of N. gonorrhoeae lipid A confers a competitive advantage during genital tract infection. The competitive index (CI) was equal to [FA1090
lptA or C=FA1090 lptA/FA1090 (output)]/[FA1090 lptA or C=FA1090 lptA/FA1090 (input)]. (A) Competitive infections in female BALB/c mice (n  7)
with FA1090 lptA and FA1090; (B) female BALB/c mice (n  7) with C=FA1090 lptA and FA1090; (C) male volunteers (n  6) with FA1090 lptA and FA1090.
Note the different y axis scale in panel C, imposed by the limit of detection of 100-fold-decreased fitness in experimental human infections. (A and C) A CI of 1
indicates that the mutant is less fit than the wild type. Solid circles indicate mice from which both wild-type N. gonorrhoeae FA1090 and FA1090 lptA were
recovered (A) and both wild-type N. gonorrhoeae FA1090 and C=FA1090 lptA/FA1090 were recovered (B). Open circles indicate infected mice or men from
whom only wild-type N. gonorrhoeae FA1090 was recovered (A and C) or only C=FA1090 lptA was recovered (B). Horizontal bars indicate geometric mean CIs.
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studies with inocula containing only N. gonorrhoeae FA1090 or
FA1090 lptA are needed to confirm whether PEA-decorated
lipid A plays dual immunostimulatory and protective roles during
male urethral infection. The demonstrated impaired fitness of
N. gonorrhoeae mutants lacking PEA in men and female mice val-
idates gonococcal LptA as an important target for development of
novel immunoprophylactic strategies or antimicrobial treatments
for gonorrhea in males and females in the face of diminishing
treatment options.
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